Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEAL-RT: De-escalated Radiotherapy after Induction Chemoimmunotherapy in LA-HNSCC
NCT07791602Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2026
- Primary completion
- Jun 2031
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 2 years. Started Jun 2026; status: active, not recruiting.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07791602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791602.